肌萎缩侧索硬化
失智症
匹兹堡化合物B
生物标志物
化学
内科学
内分泌学
痴呆
分子生物学
医学
生物
生物化学
疾病
作者
Mara Bourbouli,Michael Rentzos,Anastasia Bougea,Vasiliki Zouvelou,Vasilios C. Constantinides,Ioannis Zaganas,Ioannis Evdokimidis,Elisabeth Kapaki,George P. Paraskevas
出处
期刊:Dementia and Geriatric Cognitive Disorders
[S. Karger AG]
日期:2017-01-01
卷期号:44 (3-4): 144-152
被引量:42
摘要
<b><i>Background:</i></b> Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are nowadays recognized as spectrum disorders with a molecular link, the TAR DNA-binding protein 43 (TDP-43), rendering it a surrogate biomarker for these disorders. <b><i>Methods:</i></b> We measured cerebrospinal fluid (CSF) levels of TDP-43, beta-amyloid peptide with 42 amino acids (Aβ<sub>42</sub>), total tau protein (τ<sub>T</sub>), and tau protein phosphorylated at threonine 181 (τ<sub>P-181</sub>) in 32 patients with ALS, 51 patients with FTD, and 17 healthy controls. Double-sandwich commercial enzyme-linked immunosorbent assays were used for measurements. <b><i>Results:</i></b> Both ALS and FTD patients presented with higher TDP-43 and τ<sub>T</sub> levels compared to the control group. The combination of biomarkers in the form of the TDP-43 × τ<sub>T</sub> / τ<sub>P-181</sub> formula achieved the best discrimination between ALS or FTD and controls, with sensitivities and specificities >0.8. <b><i>Conclusion:</i></b> Combined analysis of TDP-43, τ<sub>T</sub>, and τ<sub>P-181</sub> in CSF may be useful for the antemortem diagnosis of ALS and FTD.
科研通智能强力驱动
Strongly Powered by AbleSci AI